A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection
Latest Information Update: 18 Dec 2025
At a glance
- Drugs BX 004 (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- Sponsors BiomX
Most Recent Events
- 08 Dec 2025 According to BiomX media release, Status changed from recruiting to discontinued.
- 08 Dec 2025 According to BiomX media release, Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial.
- 26 Nov 2025 Results published in the Media Release